pertuzumab

Related by string. Pertuzumab * * *

Related by context. All words. (Click for frequent words.) 79 bevacizumab Avastin ® 79 Pertuzumab 78 HGS# 78 mapatumumab 78 BRAF inhibitor 77 neratinib 77 Imprime PGG 77 sorafenib Nexavar 76 erlotinib Tarceva ® 76 enzastaurin 75 ixabepilone 75 iniparib 75 elotuzumab 75 evaluating tivozanib 75 docetaxel Taxotere 75 tanespimycin 75 Aflibercept 75 lapatinib Tykerb 75 pegylated liposomal doxorubicin 75 cilengitide 74 sorafenib Nexavar ® 74 teriflunomide 74 IMC A# 74 alvespimycin 74 thalidomide Thalomid 74 receptor tyrosine kinase inhibitor 74 CBLC# 74 docetaxel Taxotere R 74 galiximab 74 vorinostat 74 Herceptin trastuzumab 74 trastuzumab Herceptin R 74 bevacizumab Avastin 74 INCB# [001] 74 dasatinib Sprycel 74 cetuximab Erbitux ® 74 MGd 74 MAGE A3 ASCI 74 HER2 positive metastatic breast 74 ZACTIMA 73 axitinib 73 GW# [003] 73 YONDELIS 73 ganetespib 73 obatoclax 73 Zolinza 73 gemcitabine Gemzar 73 HuMax EGFr 73 mycophenolate mofetil 73 angiogenesis inhibitor 73 docetaxel chemotherapy 73 bortezomib Velcade R 73 Trastuzumab 73 pomalidomide 73 FOLFOX6 chemotherapy regimen 73 trastuzumab Herceptin 73 standard chemotherapy regimen 73 mTOR inhibitor 73 carboplatin paclitaxel 72 BAY #-# 72 cediranib 72 talabostat 72 AEG# 72 gemcitabine chemotherapy 72 Cloretazine 72 HGS ETR1 72 Dasatinib 72 cetuximab Erbitux 72 bendamustine 72 gefitinib Iressa 72 Phase Ib II 72 capecitabine Xeloda 72 paclitaxel Taxol 72 Fludara 72 temsirolimus 72 Tarceva erlotinib 72 dacetuzumab 72 Deforolimus 72 Targretin 72 PSMA ADC 72 proteasome inhibitor bortezomib 72 bortezomib Velcade 72 sorafenib tablets 72 regorafenib 72 ZOLINZA 72 Proxinium TM 72 trastuzumab DM1 72 motesanib 72 T DM1 72 nab paclitaxel 72 decitabine 72 HuLuc# 72 Revlimid lenalidomide 72 sunitinib malate 72 forodesine 72 dasatinib Sprycel ® 72 Vandetanib 72 metastatic colorectal 71 Nexavar ® 71 Phase Ib clinical 71 Ceflatonin 71 docetaxel Taxotere ® 71 Nexavar sorafenib 71 reslizumab 71 PRT# 71 rNAPc2 71 Xelox 71 5 FU leucovorin 71 gemcitabine carboplatin 71 ritonavir boosted 71 Panzem R NCD 71 Taxotere ® 71 Elotuzumab 71 phase IIa clinical 71 CYT# potent vascular disrupting 71 OMP #M# 71 olaparib 71 dexpramipexole 71 Velcade bortezomib 71 zalutumumab 71 Sorafenib 71 LY# [003] 71 Dapagliflozin 71 Quinamed 71 assessing T DM1 71 TLK# 71 5 fluorouracil leucovorin 71 IMA# 71 metastatic hormone refractory 71 metaglidasen 71 Temsirolimus 71 tocilizumab 71 KRN# 71 multi kinase inhibitor 71 Gemzar ® 71 Femara letrozole 71 chemotherapy FOLFOX 71 Bevacizumab 71 vidofludimus 71 cetuximab Erbitux R 71 entinostat 71 Degarelix 71 DU #b 71 cabazitaxel 71 goserelin 71 Blinatumomab 71 Ixempra 71 PKC# 71 PARP inhibitor 71 Enzastaurin 71 deforolimus 71 CCX# 71 inhibitor RG# 71 etanercept Enbrel 71 XmAb# 71 Panzem NCD 71 ELACYT 71 fosbretabulin 71 Doxil 71 Fludara ® 71 Aliskiren 71 OXi# 71 CA4P 70 liposomal doxorubicin 70 oral deforolimus 70 AVASTIN 70 BRIM2 70 Pegasys ® 70 dasatinib 70 Irinotecan 70 preclinically 70 FOLFIRI 70 hormone refractory metastatic prostate 70 figitumumab 70 chemotherapeutic regimen 70 mertansine 70 AEGR 70 imatinib Gleevec ® 70 paclitaxel Taxol ® 70 Telcyta 70 tipranavir 70 lintuzumab 70 sorafenib Nexavar R 70 idarubicin 70 PEG SN# 70 FOLFOX6 70 boosted protease inhibitor 70 HSP# inhibitor 70 MEK inhibitor 70 Doxil ® 70 Phase 1b trial 70 Annamycin 70 ocrelizumab 70 ZD# [001] 70 phase IIb clinical 70 CoFactor 70 adecatumumab 70 GRN#L 70 metastatic castration resistant 70 vandetanib 70 Cloretazine ® 70 Pemetrexed 70 aflibercept 70 APTIVUS 70 sunitinib 70 recurrent glioblastoma multiforme 70 farletuzumab 70 Bezielle 70 Campath alemtuzumab 70 investigational humanized monoclonal antibody 70 adalimumab Humira 70 multitargeted 70 RG# [001] 70 Tyrima 70 EndoTAGTM 1 70 gemcitabine Gemzar ® 70 Vitaxin 70 OncoVEX GM CSF 70 nucleoside analog 70 pan HDAC inhibitor 70 tyrosine kinase inhibitor 70 temozolomide 70 vemurafenib 70 Ocrelizumab 70 relapsed MM 70 Amrubicin 70 antibody MAb 70 Taxotere docetaxel 70 Azedra 70 capecitabine Xeloda R 70 Sym# 70 Avastin bevacizumab 69 Vidaza azacitidine 69 PSN# [002] 69 Rituxan rituximab 69 oral ridaforolimus 69 infusional 5-FU/LV 69 pegfilgrastim 69 erlotinib Tarceva 69 Alocrest 69 PXD# 69 Aplidin 69 tesmilifene 69 Omnitarg 69 Tarceva TM 69 Tanespimycin 69 infliximab Remicade 69 gemcitabine cisplatin 69 vascular disrupting agent 69 trabectedin 69 MEK inhibitors 69 Neoadjuvant 69 Vidaza ® 69 imatinib Gleevec 69 molecularly targeted 69 MabThera rituximab 69 PF # [002] 69 liposomal formulation 69 DFMO 69 elacytarabine 69 placebo controlled clinical 69 uric acid lowering 69 alkylating agent 69 Talabostat 69 Amplimexon 69 seliciclib 69 Xeloda ® 69 multicenter Phase II 69 prostate cancer HRPC 69 lenalidomide Revlimid 69 Elvitegravir 69 nilotinib Tasigna 69 Erbitux cetuximab 69 standard chemotherapy regimens 69 Mipomersen 69 oral Xeloda 69 relapsed multiple myeloma 69 metastatic HRPC 69 relapsed ovarian cancer 69 nucleotide analogue 69 lenalidomide dexamethasone 69 EGFR inhibitors 69 Phase Ib study 69 refractory chronic lymphocytic 69 ThermoDox R 69 temozolomide TMZ 69 gemcitabine 69 cangrelor 69 neoadjuvant treatment 69 Seliciclib 69 TTF Therapy 69 SUTENT 69 TRO# 69 radiation sensitizer 69 Archexin 69 viral kinetics 69 Bortezomib 69 IAP inhibitor 69 riociguat 69 phase IIb trial 69 Panitumumab 69 lenalidomide Revlimid R 69 tyrosine kinase inhibitors 69 virus HCV protease inhibitor 69 proteasome inhibitors 69 abiraterone 69 Aptivus ® 69 paclitaxel cisplatin 69 IL# PE#QQR 69 FOLFOX4 69 oral prodrug 69 IAP inhibitors 69 Xanafide 69 PI3K/Akt pathway inhibitor 69 HGS ETR2 69 panitumumab Vectibix 69 pegylated interferon alfa 2b 69 ELOXATIN 69 Panzem R 69 Virulizin ® 69 rosuvastatin #mg 69 Chemophase 69 BZL# 69 metastatic renal cell carcinoma 69 phase Ib 69 Neulasta ® 69 CIMZIA TM certolizumab pegol 69 tremelimumab 69 Tarvacin 69 Factor VIIa 69 metastatic malignant 69 tipifarnib 69 histone deacetylase HDAC inhibitor 69 Folfox 69 VNP#M 69 ENMD # 69 PD LID 69 Pralatrexate 69 oral anticoagulant 68 luteinizing hormone releasing 68 LHRH receptor positive 68 relapsing multiple sclerosis 68 EFAPROXYN 68 eniluracil 68 protein kinase inhibitor 68 irinotecan chemotherapy 68 MetMAb 68 sunitinib Sutent ® 68 DOXIL 68 rituximab Rituxan 68 chemotherapeutic drug 68 Nanobody 68 proteasome inhibitor 68 Carfilzomib 68 biologic therapy 68 atrasentan 68 IMC #B 68 Copegus ribavirin 68 relapsed refractory multiple myeloma 68 GSK# [001] 68 baminercept 68 visilizumab 68 pazopanib 68 refractory AML 68 Leukine 68 Myocet 68 Erlotinib 68 Cloretazine R VNP#M 68 rALLy clinical trial 68 metastatic CRC 68 tenofovir emtricitabine 68 letrozole Femara 68 Phase IIIb clinical 68 PLX# 68 Sapacitabine 68 anti EGFR antibody 68 Lapatinib 68 Daclizumab 68 depsipeptide 68 Traficet EN 68 histone deacetylase inhibitor 68 anastrozole Arimidex 68 neoadjuvant 68 dexamethasone Decadron 68 Omacetaxine 68 Combination therapy 68 APTIVUS r 68 huC# DM4 68 SERMs 68 custirsen 68 CIMZIA ™ 68 eprotirome 68 Allovectin 7 68 Phase #b/#a clinical 68 exemestane Aromasin 68 OMP #R# 68 GSK# [002] 68 Zybrestat 68 polymerase inhibitor 68 angiotensin receptor blocker ARB 68 phase IIb 68 Tykerb lapatinib 68 vinca alkaloid 68 EOquin TM 68 Fulvestrant 68 Asentar 68 pharmacodynamic effects 68 randomized Phase IIb 68 CR# vcMMAE 68 lumiliximab 68 anakinra 68 mRCC 68 CIMZIA TM 68 Taxol paclitaxel 68 xanthine oxidase inhibitor 68 HQK 68 Jevtana 68 anti angiogenic agents 68 trastuzumab 68 Teriflunomide 68 otelixizumab 68 aflibercept VEGF Trap 68 ACTEMRA TM 68 sorafenib 68 ToGA 68 evaluating satraplatin 68 SCH # 68 estramustine 68 PDE4 inhibitor 68 MyVax R 68 Golimumab 68 Phase 1b clinical trials 68 superficial bladder cancer 68 ATL# [001] 68 bortezomib 68 immunomodulator 68 chemoradiotherapy 68 TELCYTA 68 Ceplene/IL-2 68 tubulin inhibitor 68 Vilazodone 68 PEGylated Fab fragment 68 bevacizumab Avastin R 68 dacarbazine 68 CLORETAZINE TM VNP#M 68 ospemifene 68 aleglitazar 68 Phase #b/#a 68 FOLOTYN ® 68 neoadjuvant chemotherapy 68 abatacept Orencia 68 OncoVEX 68 R#/MEM # 68 anticancer therapies 68 Epratuzumab 68 NXL# 68 ularitide 68 gamma secretase inhibitor 68 BMS # 68 Afatinib 68 DEB# 68 microtubule inhibitor 68 oxaliplatin Eloxatin 68 Azixa 68 plus dexamethasone 68 mTOR inhibitors 68 midstage clinical 68 BCX# 68 Laquinimod 68 Camptosar ® 68 Pegasys R 67 Ozarelix 67 hA# 67 phase IIb study 67 velafermin 67 novel VDA molecule 67 muraglitazar 67 Azacitidine 67 investigational protease inhibitor 67 CINQUIL 67 fulvestrant 67 Onconase 67 oral antiviral 67 OvaRex ® MAb 67 ribavirin RBV 67 idraparinux 67 topotecan 67 anti angiogenic agent 67 selective androgen receptor modulator 67 ASA# 67 Hycamtin 67 tarenflurbil 67 Pegylated Interferon 67 KRAS mutations occur 67 darapladib 67 Mitoxantrone 67 posaconazole 67 NVA# 67 irinotecan doxorubicin oxaliplatin paclitaxel 67 LHRH antagonists 67 ChronVac C R 67 metastatic androgen independent 67 CRLX# 67 Gemcitabine 67 Phase 1b 67 oblimersen 67 pemetrexed Alimta 67 evaluating Nexavar 67 RhuDex ® 67 RGB # 67 pegylated interferon alfa 2a 67 multikinase inhibitor 67 orally administered inhibitor 67 diabetic neuropathic pain 67 EndoTAG TM -1 67 corticosteroid dexamethasone 67 APTIVUS R 67 palifosfamide 67 bicalutamide 67 refractory metastatic 67 immunotherapeutic vaccine 67 Tesetaxel 67 CD# antibody [001] 67 TELINTRA 67 Phase IIb clinical trials 67 romidepsin 67 Lenalidomide 67 cisplatin gemcitabine 67 oral rivaroxaban 67 FOLFOX chemotherapy 67 azacitidine 67 Hepatocellular Carcinoma HCC 67 Torisel 67 IRX 2 67 ErbB2 positive 67 FOLPI 67 volociximab 67 orally bioavailable 67 OncoVex 67 trastuzumab DM1 T DM1 67 Phase Ib clinical trials 67 antimetabolite 67 nilotinib Tasigna ® 67 VA# [002] 67 Gefitinib 67 JAK inhibitor 67 Factor Xa inhibitor 67 Curaxin CBLC# 67 LymphoStat B belimumab 67 Peg IFN 67 Onrigin 67 apremilast 67 Boceprevir 67 Pazopanib 67 temsirolimus Torisel ® 67 CD3 monoclonal antibody 67 HMG CoA reductase inhibitors 67 lexidronam injection 67 docetaxel 67 thetreatment 67 TACI Ig 67 HDACi 67 TYKERB 67 Telintra 67 interferon alfa 67 TKI therapy 67 Glufosfamide 67 huN# DM1 67 afatinib 67 Symadex 67 pemetrexed 67 melphalan prednisone 67 investigational therapies 67 refractory CLL 67 ACTEMRA 67 pegylated interferon alpha 67 interferon beta therapy 67 azacytidine 67 antitumor activity 67 registrational trial 67 Phase Ib 67 bortezomib Velcade ® 67 VAPRISOL 67 Cytoxan 67 YONDELIS R 67 NPC 1C 67 MDV# 67 Romidepsin 67 gemcitabine Gemzar R 67 plasma kallikrein inhibitor 67 non nucleoside inhibitor 67 systemic RNAi therapeutic 67 TBC# 67 Personalized Immunotherapy 67 Eculizumab 67 DAVANAT 67 alfa 2a 67 randomized Phase III 67 RoACTEMRA 67 crizotinib PF # 67 vascular disrupting agents 67 Phase IIa trials 67 vicriviroc 67 TNF Tumor Necrosis Factor 67 Pharmacokinetics PK 67 raltegravir 67 OHR/AVR# 67 CTAP# Capsules 67 INCB# [003] 67 cyclophosphamide methotrexate 67 panobinostat 67 humanised monoclonal antibody 67 Zarnestra 67 radezolid 67 Combo Stent 67 Exemestane 67 plus gemcitabine 67 AVE# 67 ofatumumab HuMax CD# 67 thymalfasin 67 imetelstat 67 M2 subunit 67 alpha 2a 67 cathepsin K inhibitor 67 acyclovir Lauriad R 67 edifoligide 67 Vicinium TM 67 Bicifadine 67 kinase inhibitor 67 GAMMAGARD 67 acadesine 67 Capesaris 67 anthracycline taxane 67 Phase IIb trials 67 TORISEL 67 vismodegib 67 Aplidin R 67 Cetuximab Erbitux 67 PEG Interferon lambda 67 PNP inhibitor 67 Xeloda capecitabine 67 demonstrated antitumor activity 67 Phase 2a trial 67 JAK inhibitors 67 somatostatin analogue 67 atacicept 67 Bosutinib 67 Trastuzumab DM1 67 PI3K inhibitor 67 predictive biomarkers 67 MGCD# [001] 67 RLY# 67 oral Factor Xa 67 PegIFN RBV 67 neurologic progression 67 targeted radiotherapeutic 67 Gleevec resistant 67 GLPG# 67 varespladib 67 plus prednisone 67 antiangiogenic therapy 67 antiangiogenic agent 66 sargramostim 66 SABCS 66 R sorafenib tablets 66 cisplatin vinorelbine 66 alefacept 66 hormone LHRH antagonist 66 Sprycel dasatinib 66 PhG alpha 1 66 trastuzumab emtansine T DM1 66 alemtuzumab Campath 66 pediatric acute lymphoblastic 66 midstage trials 66 Telatinib 66 Aurora kinase inhibitor 66 GRN# 66 #I TM# 66 leukemia AML 66 CHOP chemotherapy 66 protease inhibitor PI 66 ISIS # 66 CANCIDAS 66 CYC# 66 Muraglitazar 66 DAPT 66 fluoropyrimidine 66 GMX# 66 signal transduction inhibitors 66 chemotherapy gemcitabine 66 recurrent NSCLC 66 Squalamine 66 VEGF inhibitors 66 Neulasta R 66 RE LY 66 aromatase inhibitors AIs 66 Dacogen decitabine 66 Safinamide 66 Tasimelteon 66 BCIRG 66 NATRECOR R 66 donepezil Aricept 66 etoposide 66 investigational HCV polymerase 66 IgG1 monoclonal antibody 66 Genentech Rituxan 66 IgG1 antibody 66 Vicriviroc 66 evaluating T DM1 66 Tavocept 66 flavopiridol 66 PROCHYMAL 66 Neuvenge 66 Hormone Refractory Prostate Cancer 66 TASKi2 66 PEGylated interferon beta 1a 66 Taxotere chemotherapy 66 FASLODEX 66 zanolimumab 66 Allovectin 7 ® 66 pegylated interferons 66 CEQ# 66 Paraplatin ® 66 opioid induced bowel dysfunction 66 Gemzar gemcitabine 66 XELOX 66 Neupogen ® 66 TREANDA 66 PEG IFN 66 Vidaza R 66 platelet inhibitor 66 IIa trial 66 Tocilizumab 66 metastatic renal cell 66 trastuzumab Herceptin ® 66 rindopepimut 66 pain palliation 66 Insegia 66 sunitinib Sutent 66 nucleoside analogues 66 Vidofludimus 66 cyclophosphamide chemotherapy 66 HIF PH inhibitors 66 AKT inhibitor 66 Fludarabine 66 SAR# [004] 66 Hycamtin ® 66 Gleevec imatinib 66 dose dexamethasone 66 dose escalation clinical 66 Noxafil 66 AZD# 66 MYDICAR ® 66 AMD# [003] 66 Darusentan 66 efficacy tolerability 66 RhuDex R 66 Gleevec imatinib mesylate 66 castrate resistant prostate cancer 66 HCV protease inhibitor 66 ON #.Na 66 FLT3 66 Eli Lilly Gemzar 66 Tarvacin TM 66 microwave hyperthermia 66 metastatic pancreatic 66 lixisenatide 66 milatuzumab 66 Vaprisol 66 JAK2 inhibitor 66 Proellex TM 66 ISF# 66 ibandronate 66 immune modulating 66 comparator arm 66 LUX Lung 66 Roche Pegasys 66 miconazole Lauriad ® 66 sapacitabine 66 nucleoside reverse transcriptase inhibitor 66 DCVax R 66 darunavir ritonavir 66 cetuximab 66 paclitaxel Taxol R 66 celgosivir 66 Angiolix 66 favorable pharmacokinetic profile 66 bevacizumab 66 Ophena TM 66 IMGN# 66 active comparator 66 Telavancin 66 daunorubicin 66 NOX E# 66 oral chemotherapeutic agent 66 GVAX 66 somatostatin analog 66 Telmisartan 66 lomitapide 66 AGILECT R 66 HCV SPRINT 66 tenofovir Viread 66 Ridaforolimus 66 paclitaxel poliglumex 66 glufosfamide 66 Cimzia TM 66 ORENCIA R 66 primary hypercholesterolemia 66 Tesmilifene 66 sipuleucel T 66 Bosentan 66 TG# [003] 66 5-FU/LV 66 Elagolix 66 SNT MC# 66 cisplatin chemotherapy 66 NP2 Enkephalin 66 mecamylamine 66 relapsed myeloma 66 TYZEKA 66 FTY# 66 IGF 1R inhibitor 66 preclinical efficacy 66 lapatinib 66 AP# [003] 66 RhuDex TM 66 Phase IIIb study 66 humanized anti 66 LBH# 66 ABVD 66 LY# [002] 66 Cetuximab 66 investigational monoclonal antibody 66 perifosine 66 Troxatyl 66 EGFR TKI 66 Mylotarg 66 antithrombotic 66 heavily pretreated 66 gadobutrol 66 TNF inhibitor 66 tolvaptan 66 Roche Xeloda 66 pioglitazone HCl 66 EGFr 66 HCV RESPOND 2 66 leukemia CLL 66 COPEGUS 66 factor Xa inhibitor 66 EOquin 66 Alemtuzumab 66 fluvastatin 66 TriRima 66 LAF# 66 subcutaneous formulation 66 bicifadine 66 5 Fluorouracil 66 Treanda 66 integrase inhibitor 66 vinorelbine 66 PARP inhibitors 66 Avastin Tarceva 66 anticancer therapy 66 Denufosol 66 adjuvant colon cancer 66 TASKi3 66 Myelodysplastic Syndrome MDS 66 antitumor effect 66 Ceflatonin R 66 pharmacokinetic PK study 66 Iressa gefitinib 66 VELCADE melphalan 66 adriamycin 66 Triapine 66 Theratope 66 leflunomide 66 TNF antagonists 66 YERVOY 66 AZT zidovudine Retrovir 66 anti leukemic 66 ZK EPO 66 mGluR2 NAM 66 resistant ovarian cancer 66 Thiarabine 66 AZILECT R 66 antibody trastuzumab 66 generation purine nucleoside 66 Hsp# Inhibitor 66 anticancer agents 66 ADP receptor antagonist 66 molecularly targeted therapy 66 trodusquemine 66 beta 1a 66 OMNARIS HFA 66 iclaprim 66 FOLFOX 66 APOPTONE 66 Ixabepilone 66 TMC# C# 66 CDK inhibitor 66 PF # [001] 66 elvitegravir 66 Everolimus 66 Abiraterone 66 Epirubicin 66 Zoraxel 66 peg interferon 66 Melphalan 66 metastatic colorectal carcinoma 66 interferon gamma 1b 66 QVA# 66 combretastatin A4 phosphate CA4P 65 Phase 2b study 65 cell lymphoma CTCL 65 Bazedoxifene 65 monotherapy 65 valopicitabine 65 doxorubicin docetaxel 65 REOLYSIN ® 65 DXL# 65 interferon ribavirin 65 anti angiogenic therapy 65 ALK inhibitor 65 maximally tolerated dose 65 multicenter Phase 65 zoledronic acid 65 nilotinib 65 Alfimeprase 65 PI3K/mTOR 65 Phase 1b clinical 65 dexanabinol 65 Olaparib 65 drug conjugate 65 TMC# r 65 abiraterone acetate 65 amrubicin 65 albiglutide 65 glatiramer acetate 65 Faslodex 65 PEG interferon 65 ongoing Phase 1b 65 immunotherapeutic agent 65 bosutinib 65 Voreloxin 65 OvaRex 65 brivaracetam 65 BCR ABL inhibitor 65 Dacogen injection 65 selective modulator 65 irbesartan 65 oral antidiabetic 65 anticancer agent 65 immunomodulatory therapy 65 HCD# [002] 65 AVONEX ® 65 fenofibric acid 65 MEK Inhibitor 65 trabedersen 65 Cloretazine VNP#M 65 Eribulin 65 cannabinor 65 Urocortin 2 65 HyACT 65 Navelbine 65 Atrasentan 65 nucleoside analogs 65 multiple myeloma MM 65 targeted antifolate 65 sitaxsentan 65 recurrent GBM 65 antiangiogenic 65 TO AVOID PREGNANCY WHILE 65 direct thrombin inhibitors 65 chemotherapy docetaxel 65 Arranon 65 oral anticancer 65 esophageal candidiasis 65 Phase #b/#a trial 65 epigenetic therapies 65 HER2 overexpression 65 refractory prostate cancer 65 STRIDE PD 65 rHuPH# 65 tezampanel 65 Sanofi Aventis Taxotere 65 clevidipine 65 imatinib therapy 65 signal transduction inhibitor 65 canakinumab 65 BRAF inhibitors 65 phase IIa 65 immunoconjugate 65 invasive candidiasis 65 lipid lowering therapies 65 aurora kinase 65 HuMax CD# 65 HER2 antibody 65 octreotide implant 65 PREZISTA rtv

Back to home page